ESR1 and COVID-19: Summarizing the above data suggests that ER modulation may be a suitable pharmacological approach for preventing/attenuating the cytokine storm and inflammation associated with COVID-19, and in particular the use of SERMs, specifically raloxifene, may represent a promising pharmacological option.